Clinical Trial Details
| Trial ID: | L0588 |
| Source ID: | JPRN-UMIN000021291 |
| Associated Drug: | Pioglitazone |
| Title: | |
| Acronym: | -- |
| Status: | Not Recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Nonalcoholic fatty liver disease patients with type 2 diabetes |
| Interventions: | Dapagliflozin 5mg Sig. 1 or 2 tab po once time a day<br>Pioglitazone 15mg Sig. 1 or 2 tab po once time a day<br>Glimepiride 0.5 or 1mg Sig. 1 or 3 tab po once or two times a day |
| Outcome Measures: | Change of liver function and L/S ratio (CT) six months after the interventionChange of body weight, visceral fat amount, fasting plasma glucose (FPG), insulin, triacylglycerol (TG), non-esterified fatty acid (NEFA), HDL-cholesterol, LDL-cholesterol, lipoprotein fractionation, adiponectin, hsCPR, TNF-alpha, MCP-, MDA, typIV collagen7S, P-III-P, M2BP, the fibrosis score (NAFLD fibrosis score, FIB-4 index, APRI, BARD score, BAAT score), proinsulin/S-CPR ratio |
| Sponsor/Collaborators: | Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism |
| Gender: | All |
| Age: | 20years-oldNot applicable |
| Phases: | Not selected |
| Enrollment: | 90 |
| Study Type: | Interventional |
| Study Designs: | Parallel Randomized |
| Start Date: | 02/03/2016 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 2 April 2019 |
| Locations: | Japan |
| URL: | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021576 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D275 | Pioglitazone | Chemical drug | DB01132 | PPARG agonist | Improve insulin resistance | Advanced in clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D101 | Dapagliflozin | Chemical drug | DB06292 | SLC5A2 antagonist; SLC5A2 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D154 | Glimepiride | Chemical drug | DB00222 | ABCC8 binder; KCNJ1 inhibitor; KCNJ11 inhibitor; KCNJ11 potassium channel inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |